如何接近高风险髓瘤从诱导到复发?
Katja C Weisel1, Christoph Schaefers1, Lisa B Leypoldt1,2
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hematology. American Society of Hematology. Education Program
|December 5, 2025
概括
高风险多发性骨髓瘤 (MM) 的治疗具有挑战性. 前期四重治疗和最小的残留疾病负面影响改善了结果,而免疫疗法为复发患者提供了新的希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 高风险多发性骨髓瘤 (HRMM) 仍然是一个重要的治疗挑战,尽管在治疗方面取得了进展.
- 定义HRMM传统上依赖于细胞遗传异常,最近的修订包括基因组分期.
- 早期识别HRMM对于引导患者制定最佳治疗策略至关重要.
研究的目的:
- 对高风险多发性骨髓瘤的当前治疗方法进行审查.
- 突出实现最小残留疾病负面影响的重要性.
- 讨论针对复发性或耐火性HRMM的新兴免疫疗法.
主要方法:
- 对临床试验中新出现的数据的审查,重点是HRMM患者.
- 对HRMM的修订标准的分析,包括基因组分期.
- 评估前期四倍治疗,自身干细胞移植和维护策略的结果.
主要成果:
- 前期四重治疗,其次是巩固和维护,包括高剂量的梅尔法兰和自身干细胞移植,改善了预后.
- 实现持续的最小残留病负反应是预防早期复发的首要治疗目标.
- 针对B细胞成熟的抗原导向免疫疗法,包括CAR T细胞,在功能性HRMM患者中显示出有利的结果.
结论:
- 针对HRMM的最佳前线治疗包括针对深度,持续反应的强化初始治疗.
- 持续治疗和维护对于避免耐药性和早期复发至关重要.
- 免疫疗法是治疗复发性高风险多发性骨髓瘤的一个有希望的进步.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
30.3K
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
9.0K
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
